Cochrane · systematic review · CD002311
Late (≥ 7 days) inhaled corticosteroids to reduce bronchopulmonary dysplasia in preterm infants
Onland, W, Offringa, M, van Kaam, A · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
4
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 4 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyInhaled corticosteroids compared to placebo in preterm infants
Population: preterm infants
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Combined outcome of mortality or BPD at 36 weeks' PMA Inhaled corticosteroids vs placebo | RR 1.1 [0.74, 1.63] | 1 study · 30 participants | Very low Downgraded: imprecision, inconsistency, publication bias |
Mortality at 36 weeks' PMA Inhaled corticosteroids vs placebo | RR 3 [0.35, 25.78] | 3 studies · 61 participants | Very low Downgraded: imprecision, publication bias |
BPD at 36 weeks' PMA Inhaled corticosteroids vs placebo | RR 1 [0.59, 1.7] | 1 study · 30 participants | Very low Downgraded: imprecision, inconsistency, publication bias |
Open‐label use of systemic corticosteroids Inhaled corticosteroids vs placebo | RR 0.51 [0.26, 1] | 4 studies · 74 participants | Very low Downgraded: imprecision, inconsistency |
Inhaled corticosteroids versus placebo to reduce bronchopulmonary dysplasia in preterm infants
Population: preterm infants
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Combined outcome mortality or bronchopulmonary dysplasia at 36 weeks postmenstrual age Inhaled corticosteroids vs placebo to reduce bronchopulmonary dysplasia | RR 1.1 [0.74, 1.63] | 1 study · 30 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |
Mortality at 36 weeks postmenstrual age Inhaled corticosteroids vs placebo to reduce bronchopulmonary dysplasia | RR 3 [0.35, 25.78] | 3 studies · 61 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |
Bronchopulmonary dysplasia at 36 weeks postmenstrual age Inhaled corticosteroids vs placebo to reduce bronchopulmonary dysplasia | RR 1 [0.59, 1.7] | 1 study · 30 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |
Open‐label intravenous corticosteroids Inhaled corticosteroids vs placebo to reduce bronchopulmonary dysplasia | RR 0.51 [0.26, 1] | 4 studies · 74 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |